Waiting for the “liquid revolution” in the adjuvant treatment of colon cancer patients: a review of ongoing trials
Cancer Treatment Reviews · 2024-05 · 126 · 102735
DOI: 10.1016/j.ctrv.2024.102735 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Treatment Reviews, 2024-05. Verfasst von V Conca und 5 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy; Department of Translational Research and New Technologies in Medic…. Hauptthemen laut MEDLINE: Colonic Neoplasms, Circulating Tumor DNA. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Commission, Ministero dell’Istruzione, dell’Università e della Ricerca.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Since colon cancer has a high rate of shedding of tumour fragments into the blood, several research efforts are now focused on the investigation of the minimal residual disease through the detection of ctDNA to tailor the adjuvant therapy of colon cancer patients and optimize its cost/effectiveness balance. The negative prognostic impact of detectable ctDNA in patients' blood after radical surgery for colon cancer is well established. Several clinical trials adopting heterogeneous designs and techniques are now ongoing to translate promises into daily practice by answering five general questions: i) is a ctDNA-guided decision making efficacious in the post-operative management of colon cancer patients? ii) are de-escalation strategies possible in ctDNA-negative cases? iii) are escalation strategies useful to improve the prognosis of ctDNA-positive patients? iv) when MRD is identified at the end of the adjuvant chemotherapy, is another post-adjuvant systemic therapy efficacious? v) can we exploit ctDNA technologies in the follow up of colon cancer patients? This review focuses on currently ongoing trials and how their results may affect the ctDNA "liquid revolution" of early colon cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
- Division of Medical Oncology, Policlinico Universitario Campus Bio-Medico, Rome, Italy.
- Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy. Electronic address:…
Förderung
- European Commission
- Ministero dell’Istruzione, dell’Università e della Ricerca
Zitieren
APA
Conca, V., Ciracì, P., Boccaccio, C., Minelli, A., Antoniotti, C., & Cremolini, C. (2024). Waiting for the “liquid revolution” in the adjuvant treatment of colon cancer patients: a review of ongoing trials. Cancer Treatment Reviews, 126, 102735. https://doi.org/10.1016/j.ctrv.2024.102735
Vancouver
Conca V, Ciracì P, Boccaccio C, Minelli A, Antoniotti C, Cremolini C. Waiting for the “liquid revolution” in the adjuvant treatment of colon cancer patients: a review of ongoing trials. Cancer Treatment Reviews. 2024;126:102735. doi:10.1016/j.ctrv.2024.102735
BibTeX
@article{Conca2024,
author = {Conca, V and Ciracì, P and Boccaccio, C and Minelli, A and Antoniotti, C and Cremolini, C},
title = {Waiting for the “liquid revolution” in the adjuvant treatment of colon cancer patients: a review of ongoing trials},
journal = {Cancer Treatment Reviews},
year = {2024},
volume = {126},
pages = {102735},
doi = {10.1016/j.ctrv.2024.102735}
}
EUVIMED